WO2009156837A3 - Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole - Google Patents

Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole Download PDF

Info

Publication number
WO2009156837A3
WO2009156837A3 PCT/IB2009/006056 IB2009006056W WO2009156837A3 WO 2009156837 A3 WO2009156837 A3 WO 2009156837A3 IB 2009006056 W IB2009006056 W IB 2009006056W WO 2009156837 A3 WO2009156837 A3 WO 2009156837A3
Authority
WO
WIPO (PCT)
Prior art keywords
amorphous form
indolinone
malate salt
pyrrole substituted
sunitinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/006056
Other languages
English (en)
Other versions
WO2009156837A2 (fr
Inventor
Stephen Benedict David Winter
Monica Benito Velez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medichem SA
Original Assignee
Medichem SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medichem SA filed Critical Medichem SA
Publication of WO2009156837A2 publication Critical patent/WO2009156837A2/fr
Publication of WO2009156837A3 publication Critical patent/WO2009156837A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouvelles formes de l'agent anticancéreux sunitinib de formule (I) ainsi que des sels pharmaceutiquement acceptables correspondants, et notamment du malate de sunitinib sous forme amorphe et du malate de sunitinib de forme III. L'invention concerne également un procédé de préparation correspondant et des compositions pharmaceutiques comprenant du malate de sunitinib sous forme amorphe.
PCT/IB2009/006056 2008-06-26 2009-06-26 Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole Ceased WO2009156837A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7603108P 2008-06-26 2008-06-26
US61/076,031 2008-06-26

Publications (2)

Publication Number Publication Date
WO2009156837A2 WO2009156837A2 (fr) 2009-12-30
WO2009156837A3 true WO2009156837A3 (fr) 2010-08-05

Family

ID=41445029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/006056 Ceased WO2009156837A2 (fr) 2008-06-26 2009-06-26 Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole

Country Status (1)

Country Link
WO (1) WO2009156837A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20063777B (en) 2001-08-15 2006-03-27 Upjohn Co Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof
WO2011092664A1 (fr) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Formes cristallines du sel d'acide l-malique du sunitinib
WO2011100325A2 (fr) 2010-02-09 2011-08-18 Sicor Inc. Polymorphes de sels de sunitinib
EP2802314B1 (fr) 2012-01-13 2020-11-25 XSpray Microparticles AB Procédé de production de nanoparticules hybrides amorphes stables comprenant au moins un inhibiteur de la protéine kinase et au moins un constituant polymère stabilisant et matriciel
WO2013160916A1 (fr) * 2012-04-25 2013-10-31 Hetero Research Foundation Dispersion solide de malate de sunitinib
CA2838587A1 (fr) * 2013-10-18 2015-04-18 Hari Babu Matta Forme cristalline pure ii de sel d'acide l-malique de sunitinib et procede pour sa preparation
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN105085490A (zh) * 2014-05-09 2015-11-25 上海科胜药物研发有限公司 新的舒尼替尼苹果酸盐晶型及其制备方法
WO2020216450A1 (fr) 2019-04-25 2020-10-29 Synthon B.V. Composition pharmaceutique comprenant du sunitinib amorphe
KR20240025990A (ko) * 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156292A1 (en) * 2000-02-15 2002-10-24 Tang Peng Cho Pyrrole substituted 2-indolinone protein kinase inhibitors
US20030069298A1 (en) * 2001-08-15 2003-04-10 Pharmacia & Upjohn Company Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof
US20030229229A1 (en) * 2002-02-15 2003-12-11 Qingwu Jin Process for preparing indolinone derivatives
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
WO2009067674A2 (fr) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Polymorphes de base de sunitinib et procédés pour les préparer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156292A1 (en) * 2000-02-15 2002-10-24 Tang Peng Cho Pyrrole substituted 2-indolinone protein kinase inhibitors
US20030069298A1 (en) * 2001-08-15 2003-04-10 Pharmacia & Upjohn Company Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof
US20030229229A1 (en) * 2002-02-15 2003-12-11 Qingwu Jin Process for preparing indolinone derivatives
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
WO2009067674A2 (fr) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Polymorphes de base de sunitinib et procédés pour les préparer

Also Published As

Publication number Publication date
WO2009156837A2 (fr) 2009-12-30

Similar Documents

Publication Publication Date Title
WO2009156837A3 (fr) Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2008133896A3 (fr) Agents antihypertensifs à double action
WO2008012622A3 (fr) Composés d'azabenzimidazolyle
WO2008097459A3 (fr) Agents anti hypertension à double action
WO2007141283A3 (fr) Nouveaux sels et formes de sels cristallins d'un dérivé de l'indolinone
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
TN2012000125A1 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
MY156552A (en) Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
IN2012DN03182A (fr)
WO2007150026A3 (fr) Dérivés de purinone en tant qu'agonistes de hm74a
WO2008006795A3 (fr) Composés d'indole
WO2011045232A3 (fr) Agonistes du récepteur du neuropeptide-2 (y-2r)
WO2010001257A3 (fr) Nouvelles formes à l’état solide de laquinimod et son sel de sodium
WO2010052144A3 (fr) Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations
WO2012015681A3 (fr) Conjugués médicaments-ligands, leur synthèse et intermédiaires correspondants
WO2013042135A8 (fr) Composés hétéroaryles convenant comme ligands du récepteur 5-ht4
WO2010049449A3 (fr) Nouveaux sels de sunitinib
WO2012135615A3 (fr) Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
WO2010011811A3 (fr) Composés de 3-(phénoxyphénylméthyl)pyrrolidine
IN2012DN04868A (fr)
WO2010070677A3 (fr) Procédé de préparation de prasugrel et de ses sels pharmaceutiquement acceptables
WO2007112913A3 (fr) Derives de benzimidazole
WO2011084434A3 (fr) Dérivés d'indole et d'indoline à cycles condensés et pontage aza
WO2010012459A3 (fr) Procédé de préparation de sels de solifénacine et inclusion de ces derniers dans des formes pharmaceutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09769649

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09769649

Country of ref document: EP

Kind code of ref document: A2